Gene Therapy Pioneer Dr Luigi Naldini Receives Prestigious Lifetime Achievement Award
18 January 2024
The award was presented by Sven Kili, a member of the Phacilitate Advisory Board and Judging Committee, to a roaring applause as gene therapy was celebrated by the advanced therapies industry.
The Advanced Therapies Awards ceremony held a special significance tonight as Dr. Luigi Naldini, Director of the San Raffaele Telethon Institute for Gene Therapy, was honored with the esteemed Lifetime Achievement Award. This award celebrates Dr. Naldini’s extraordinary contributions to gene therapy, a field he has helped shape through his pioneering work on lentiviral vectors.
During the evening, a specially curated dedication video was played out to the Advanced Therapies Awards audience, featuring contributions and congratulations from colleagues and peers from the gene therapy field.
Dr. Naldini’s groundbreaking research has paved the way for life-changing treatments for a multitude of devastating diseases. His dedication to developing and delivering safe and effective gene therapies has brought hope to countless patients and families.
One such testament to Dr. Naldini’s impact is the story of Arshida, a young girl who battled Mucopolysaccharidosis Type I (MPS I) before receiving gene therapy treatment. As Arshida’s mother, Golnoosh Hosseinian, tearfully expressed:
“Arshida’s treatment was the most precious gift… We were reborn with her… Words are powerless to express my gratitude… Thank you, thank you very much!”
Dr. Naldini’s influence extends far beyond his own research. He has fostered a thriving community of gene therapy experts through his mentorship and collaborations. His passion for education and scientific outreach has inspired the next generation of scientists to carry the torch of innovation in this transformative field.
“Professor Naldini embodies the term ‘innovator,’” remarked Sven Kili, Phacilitate Advisory Board member and spokesperson for the judging panel. “His unwavering dedication to finding cures has driven him through early failures and propelled the field forward.”
As Dr. Naldini receives this well-deserved recognition, his story serves as a powerful reminder of the transformative potential of gene therapy and the tireless dedication of its pioneers. His relentless pursuit of cures continues to inspire hope and pave the way for a brighter future for patients battling a multitude of diseases.
The Lifetime Achievement Award was presented amidst a celebration of excellence within the advanced therapies industry. The Advanced Therapies Awards recognize achievements in innovation, collaboration, and translation, honoring not only scientific breakthroughs but also the commitment to sustainability, diversity, and driving disruptive advancements. A full list of award winners from the evening has been announced on the dedicated awards website.
This year’s ceremony marked a new chapter for Advanced Therapies Week, as future iterations will take place in San Diego, California, starting in 2025. Nominations for the Advanced Therapies Awards 2025 will open later into 2024.
Xavier De Mollerat Du Jeu, Senior Director R&D at Thermo Fisher Scientific is accompanied by Gianluca Pettiti, Executive Vice President and President, Life Sciences Group at Thermo Fisher Scientific and Fred Parietti, Co-Founder and CEO at Multiply Labs for this Workshop at Advanced Therapies Week 2024.
Manufacturing capacity, complexity and cost are core constraints that limit commercialization of cell and gene therapies, and ultimately patient access. In this Fireside Chat series, join Georgi Makin, VP of Digital & Editorial at Phacilitate and the Germfree team as we discuss the challenges and opportunities associated with delivering cell therapies in a decentralized manufacturing model.